These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 16849647)
1. The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Aichberger KJ; Mayerhofer M; Vales A; Krauth MT; Gleixner KV; Bilban M; Esterbauer H; Sonneck K; Florian S; Derdak S; Pickl WF; Agis H; Falus A; Sillaber C; Valent P Blood; 2006 Nov; 108(10):3538-47. PubMed ID: 16849647 [TBL] [Abstract][Full Text] [Related]
2. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746 [TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140 [TBL] [Abstract][Full Text] [Related]
4. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Mayerhofer M; Florian S; Krauth MT; Aichberger KJ; Bilban M; Marculescu R; Printz D; Fritsch G; Wagner O; Selzer E; Sperr WR; Valent P; Sillaber C Cancer Res; 2004 May; 64(9):3148-54. PubMed ID: 15126353 [TBL] [Abstract][Full Text] [Related]
5. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML). Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872 [TBL] [Abstract][Full Text] [Related]
6. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Chu S; Holtz M; Gupta M; Bhatia R Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699 [TBL] [Abstract][Full Text] [Related]
7. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
8. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway. Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326 [TBL] [Abstract][Full Text] [Related]
9. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Mayerhofer M; Valent P; Sperr WR; Griffin JD; Sillaber C Blood; 2002 Nov; 100(10):3767-75. PubMed ID: 12393646 [TBL] [Abstract][Full Text] [Related]
10. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]. Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985 [TBL] [Abstract][Full Text] [Related]
11. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Mayerhofer M; Gleixner KV; Mayerhofer J; Hoermann G; Jaeger E; Aichberger KJ; Ott RG; Greish K; Nakamura H; Derdak S; Samorapoompichit P; Pickl WF; Sexl V; Esterbauer H; Schwarzinger I; Sillaber C; Maeda H; Valent P Blood; 2008 Feb; 111(4):2200-10. PubMed ID: 18024796 [TBL] [Abstract][Full Text] [Related]
12. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Topaly J; Zeller WJ; Fruehauf S Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055 [TBL] [Abstract][Full Text] [Related]
14. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
15. Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression. Cerny-Reiterer S; Ghanim V; Hoermann G; Aichberger KJ; Herrmann H; Muellauer L; Repa A; Sillaber C; Walls AF; Mayerhofer M; Valent P Neoplasia; 2012 Jul; 14(7):572-84. PubMed ID: 22904675 [TBL] [Abstract][Full Text] [Related]
16. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193 [TBL] [Abstract][Full Text] [Related]